IMPEDIMED LIMITED — Earnings Release 2015

Aug 25, 2015

26 August 2015

ASX ANNOUNCEMENT

==> picture [103 x 95] intentionally omitted <==

----- Start of picture text ----- ASX: IPD----- End of picture text -----

– Appendix 4E Financial Year Ended 30 June 2015

Brisbane, Australia - ImpediMed Limited (ASX: IPD) is pleased to report its financial results and Appendix 4E, Preliminary Final Report for the financial year ended 30 June 2015.

ImpediMed continued to increase sales, with revenue from ordinary activities of $4.9 million, up $1.3 million or 38% year on year. Lymphoedema revenue, generated from sales of the L-Dex[®] device and patient tests conducted, increased by $0.4 million or 28% year on year as the Company commenced its commercial pilots of L-Dex with a handful of leading cancer centers in the US, ahead of its full US launch planned for late CY2015.

The company reported a net loss of $14.8 million, compared to a net loss of $7.9 million in the previous year, reflecting the increased investment in sales and marketing resources in preparation for the full commercial launch of L-Dex in the US.

Operational highlights for the financial year include:

• Lymphoedema included for the first time in the NCCN Guidelines[®] for Breast Cancer, widely recognised as the standard for clinical policy in cancer care in the US;

• Successful targeted commercial launch with six leading, large US cancer centres participating in the pilot program;

• Unique CPT Category I reimbursement code for the use of ImpediMed’s BIS technology coming into effect on 1 January 2015;

• Several prestigious cancer centres, including Mayo Clinic and MD Anderson Cancer Centre, joining the post-approval clinical trial.

Managing Director and CEO, Richard Carreon said, “This past financial year has been another year of excellent progress for ImpediMed, which has seen us deliver on our planned operational milestones to lay the foundation for a successful commercial launch of L-Dex in the US later this calendar year.”

“There is growing awareness and acceptance of the need to monitor and detect lymphoedema in cancer patients, and much of this is being driven by the commercial and industry engagement efforts of ImpediMed. Notably, inclusion of lymphoedema in the NCCN Guidelines for Breast Cancer, which now recommends educating, monitoring and referring for lymphoedema management, was a very favorable outcome as we look to undertake our US market launch and drive broad market adoption of L-Dex.”

• ENDS -

Richard Carreon Managing Director & CEO

For further information contact: Richard Carreon, ImpediMed Managing Director & CEO Morten Vigeland, ImpediMed CFO T: +1 (760) 585-2100

Kyahn Williamson, Buchan Investor and Media Relations T: +61 3 9866 4722

E: kwilliamson@buchanwe.com.au

About ImpediMed

ImpediMed Limited is the world leader in the development and distribution of medical devices employing Bioimpedance Spectroscopy (BIS) technologies for use in the noninvasive clinical assessment and monitoring of fluid status. ImpediMed’s primary product range consists of a number of medical devices that aid surgeons, oncologists, therapists and radiation oncologists in the clinical assessment of patients for the potential onset of secondary lymphoedema. Pre-operative clinical assessment in cancer survivors, before the onset of symptoms, may prevent the condition from becoming a lifelong management issue and thus improve the quality of life of the cancer survivor. ImpediMed has the first medical device with an FDA clearance in the United States to aid health care professionals, clinically assess secondary unilateral lymphedema of the arm and leg in women and the leg in men.

For more information, visit: www.impedimed.com.au